While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Delve into the challenges Black Americans face with Alzheimer’s and the urgent need for better prevention, care, and ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...